Nadene Henderson

Ms. Nadene Henderson

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
BWBonnie and Neal Weinreb
Bonnie and Neal Weinreb
OGOzlem Goker-Alpan
Ozlem Goker-Alpan
PKPriya Kishnani
Priya Kishnani
NLNicola Longo
Nicola Longo
TBThomas Andrew Burrow
Thomas Andrew Burrow
Can FiciciogluCan Ficicioglu
Can Ficicioglu
Gaucher disease (GD) is an autosomal recessive inherited lysosomal storage disease that often presents in early childhood and is associated with damage to multiple organ systems. Many challenges associated with GD diagnosis and management arise from the considerable heterogeneity of disease presentations and natural history. Phenotypic classification has traditionally been based on the absence (in type 1 GD) or presence (in types 2 and 3 GD) of neurological involvement of varying severity. However, patient management and prediction of prognosis may be best served by a dynamic, evolving definition of individual phenotype rather than by a rigid system of classification. Patients may experience considerable delays in diagnosis, which can potentially be reduced by effective screening programs; however, program implementation can involve ethical and practical challenges. Variation in the clinical course of GD and an uncertain prognosis also complicate decisions concerning treatment initiation, with differing stakeholder perspectives around efficacy and acceptable cost/benefit ratio. We review the challenges faced by physicians in the diagnosis and management of GD in pediatric patients. We also consider future directions and goals, including acceleration of accurate diagnosis, improvements in the understanding of disease heterogeneity (natural history, response to treatment, and prognosis), the need for new treatments to address unmet needs for all forms of GD, and refinement of the tools for monitoring disease progression and treatment efficacy, such as specific biomarkers.

Verified
Journal Article
Open access
PDF file
Can FiciciogluCan Ficicioglu
Can Ficicioglu
RARebecca Ahrens-Nicklas
Rebecca Ahrens-Nicklas
JBJoshua Barch
Joshua Barch
SCSanmati Cuddapah
Sanmati Cuddapah
BDBrenda S. DiBoscio
Brenda S. DiBoscio
RXRui Xiao
Rui Xiao
Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is performed as a second-tier test in all newborns with low GAA enzyme activity [<2.10 micromole/L/h]. A total of 115 newborns had low GAA enzyme activity and abnormal genetic testing and were referred to metabolic centers. Two newborns were diagnosed with Infantile Onset Pompe Disease (IOPD), and 31 newborns were confirmed to have Late Onset Pompe Disease (LOPD). The incidence of IOPD + LOPD was 1:16,095. A total of 30 patients were compound heterozygous for one pathogenic and one variant of unknown significance (VUS) mutation or two VUS mutations and were defined as suspected LOPD. The incidence of IOPD + LOPD + suspected LOPD was 1: 8431 in PA. We also found 35 carriers, 15 pseudodeficiency carriers, and 2 false positive newborns.

25 September 2023 in OBM Genetics
Verified
Journal Article
Open access
PDF file
ALAshley Lahr
Ashley Lahr
NHNadene Henderson
Nadene Henderson
LWLee Williams
Lee Williams
GAGeorgianne Arnold
Georgianne Arnold
DODamara Ortiz
Damara Ortiz
Lysosomal storage disorders (LSD) are caused by enzymatic failure to degrade specific cellular byproducts of metabolism within the lysosome. They have a wide range of presentations involving multiple body systems and can manifest from infancy through adulthood. As treatments have become available for many of these disorders, newborn screening has been adapted for early identification and pre-symptomatic treatment. This article will review some of the LSD that are now being added to newborn screening panels, including globoid cell leukodystrophy (Krabbe), Gaucher disease, Fabry disease, Mucopolysaccharidosis Type I (Hurler; MPSI), Mucopolysaccharidosis Type II (Hunter; MPSII), Acid Sphingomyelinase deficiency (ASMD), and Pompe disease.

3 September 2020 in Journal of Genetic Counseling
Verified
Journal Article
Open access
PDF file
NHNadene Henderson
Nadene Henderson
LBLisa Berry
Lisa Berry
DLDawn A. Laney
Dawn A. Laney
Click on the article title to read more.